Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.946.889 €): Beyond neuroInflammation: new Concepts to Elucidate the immune system’s vital role in Parkinson’s disease Hor 04.07.2024 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Beyond neuroInflammation: new Concepts to Elucidate the immune system’s vital role in Parkinson’s disease
Decades of research into Parkinson's disease (PD) have fallen short in fully comprehending its mechanisms, leaving us without a cure. Current treatments merely alleviate symptoms temporarily, but are unable to impede the progression of the disease. Clearly, PD research has hit a wall, and new approaches are needed. Recent discoveries of the involvement of the peripheral immune system in PD have sparked a groundbreaking proposition by BICEPS: PD must be considered a systemic disease with an immune response involving both brain and periphery. Thus, to revolutionize PD research, we must shift away from the neuro-centric approach of past decades and extend our focus to studying the immune system outside the brain. Furthermore, recent advancements, such as systems biology and artificial intelligence (AI)-driven data mining, diagnosis, and drug development, hold significant promise for advancing PD research. Therefore, BICEPS is uniting PD researchers, immunologists, and experts in AI and systems biology from leading European academic institutions, startup companies, and established pharmaceutical firms into a unique consortium. The primary objective is to train a new generation of PD researchers with interdisciplinary expertise in these fields. This ambitious goal will be realized through an intensive training program that encompasses cutting-edge methodologies, encourages innovation, nurtures transferable skills, and provides immersive, hands-on research experiences. Thereby, the BICEPS network aims to shape the future of PD research by adopting a fresh perspective and expediting the development of diagnostics and therapies for PD, with a particular focus on the immune system.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Association Europeenne Pour la Maladie de Parkinson | ? |
| Aarhus Universitet | 603.576 € |
| Anacalypsis Therapeutics ΙΚΕ | 240.098 € |
| Bayer AG | 260.539 € |
| Charite - Universitaetsmedizin Berlin | 463.181 € |
| Deutsches Zentrum FUR Neurodegenerative Erkrankungen e. V. | 57.898 € |
| Ethniko Kai Kapodistriako Panepistimio Athinon | 240.098 € |
| Faculty OF Medicine, University OF Belgrade | 421.690 € |
| H. Lundbeck AS | 301.788 € |
| Metasysx GmbH | 260.539 € |
| Rijksuniversiteit Groningen | 823.111 € |
| Sulfateq B.V. | 274.370 € |
Quelle: https://cordis.europa.eu/project/id/101167843
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Parkinson's Europe, Brüssel, Belgien.